EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms

Linlin Che, Liujing Zhu, Ling Zhou, Yufu Zhou

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-04 · 1881 (2) · 189566

DOI: 10.1016/j.bbcan.2026.189566 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-04. Verfasst von Linlin Che und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Ferroptosis, Sorafenib, Liver Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 96 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, Shanghai University of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sorafenib is a cornerstone in the treatment of advanced HCC. However, its clinical efficacy is frequently limited by the development of resistance, contributing to unfavorable patient outcomes. Overcoming this resistance is therefore a critical therapeutic challenge. Emerging evidence highlights ferroptosis-a regulated cell death process driven by iron-dependent lipid peroxidation-as a promising avenue to reverse sorafenib resistance. SLC7A11 (cystine/glutamate antiporter) and GPX4 (phospholipid hydroperoxidase) cooperate to maintain redox homeostasis by supporting glutathione biosynthesis and neutralizing lipid peroxides, thereby inhibiting ferroptosis. Nrf2, a master transcriptional regulator of antioxidant responses, further enhances this defense by upregulating both SLC7A11 and GPX4, protecting HCC cells from sorafenib-induced ferroptotic death. In contrast, lipid metabolism remodels membrane phospholipid composition to promote ferroptosis resistance. This review systematically examines the key regulatory axes modulating ferroptosis in this context: the Nrf2/SLC7A11/GPX4 antioxidant axis, the parallel FSP1-CoQ10 pathway, the pro-ferroptotic ACSL4/LPCAT3 axis, and central transcriptional regulators of SLC7A11, including P53, ATF4, SAT1, and ABCC5. We synthesize recent advances linking these molecular axes to ferroptosis pathways, discuss their crosstalk in sorafenib-resistant HCC, and underscore emerging therapeutic strategies that leverage pharmacological or radiotherapeutic targeting of these mechanisms. A deeper understanding of this regulatory network may inform rational combination therapies aimed at resensitizing advanced HCC to sorafenib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularFerroptosisSorafenibLiver NeoplasmsDrug Resistance, NeoplasmAntineoplastic AgentsHumansAmino Acid Transport System y+Phospholipid Hydroperoxide Glutathione PeroxidaseAnimalsNF-E2-Related Factor 2

Stichwörter der Autor:innen

ACSL4/LPCAT3 axisFSP1-CoQ10 axisFerroptosisHepatocellular carcinomaNrf2/SLC7A11/GPX4 axisSorafenib resistance

Substanzen

SorafenibSLC7A11 protein, humanAmino Acid Transport System y+Phospholipid Hydroperoxide Glutathione PeroxidaseAntineoplastic AgentsNFE2L2 protein, humanNF-E2-Related Factor 2

Autor:innen und Institutionen

  • Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, PR China.
  • The Key Laboratory of Traditional Chinese Medicine Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, YanTai, ShanDong 26…
  • Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, PR China. Electronic address: zhouyufu@shutcm.edu.cn.

Förderung

  • Natural Science Foundation of Shanghai Municipality
  • Shanghai University of Traditional Chinese Medicine

Zitieren

APA

Che, L., Zhu, L., Zhou, L., & Zhou, Y. (2026). Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(2), 189566. https://doi.org/10.1016/j.bbcan.2026.189566

Vancouver

Che L, Zhu L, Zhou L, Zhou Y. Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(2):189566. doi:10.1016/j.bbcan.2026.189566

BibTeX
@article{Che2026,
  author = {Che, Linlin and Zhu, Liujing and Zhou, Ling and Zhou, Yufu},
  title = {Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2026},
  volume = {1881},
  number = {2},
  pages = {189566},
  doi = {10.1016/j.bbcan.2026.189566}
}
Kostenlos starten →